The hypolipidemic effect and antithrombotic activity of Mucuna pruriens protein hydrolysates.
Hydrolysates and peptide fractions (PF) obtained from M. pruriens protein concentrates with commercial and digestive enzymatic systems were studied for their hypolipidemic and antithrombotic activities. Hydrolysates obtained with Pepsin-Pancreatin (PP) and their peptide fractions inhibited cholesterol micellar solubility with a maximum value of 1.83% in PP. Wistar rats were used to evaluate the hypolipidemic effect of hydrolysates and PF. The higher reductions of cholesterol and triglyceride levels were exhibited by PP and both peptide fractions <1 kDa obtained from PP and Alcalase®-Flavourzyme® hydrolysate (AF) at a dose of 15 mg kg(-1) of animal weight. PF > 10 kDa from both hydrolysates showed the maximum antithrombotic activity with values of 33.33% for PF > 10 kDa from AF and 31.72% for PF > 10 kDa from PP. The results suggest that M. pruriens bioactive peptides with the hypolipidemic effect and antithrombotic activity might be utilized as nutraceuticals.
Facultad de Ingeniería Química, Universidad Autónoma de Yucatán. Periférico Norte Km. 33.5, Tablaje Catastral 13615, Col. Chuburná de Hidalgo Inn, 97203 Mérida, Yucatán, México. maira.segura@correo.uady.mx.
Francisco
F
Herrera Chalé
Departamento de Ingeniería Química-Bioquímica, Instituto Tecnológico de Mérida. Av. Tecnológico Km 4.5 S/N, C.P. 97118. Mérida, Yucatán, México.
Jorge Carlos
JC
Ruiz Ruiz
Facultad de Ingeniería Química, Universidad Autónoma de Yucatán. Periférico Norte Km. 33.5, Tablaje Catastral 13615, Col. Chuburná de Hidalgo Inn, 97203 Mérida, Yucatán, México. maira.segura@correo.uady.mx.
David
D
Betancur Ancona
Facultad de Medicina, Universidad Autónoma del Estado de Morelos. Calle Iztaccihuátl Esq. Leñeros S/N, Volcanes, 62350 Cuernavaca, Morelos.
Juan José
JJ
Acevedo Fernández
Facultad de Ingeniería Química, Universidad Autónoma de Yucatán. Periférico Norte Km. 33.5, Tablaje Catastral 13615, Col. Chuburná de Hidalgo Inn, 97203 Mérida, Yucatán, México. maira.segura@correo.uady.mx.
Maira Rubi
MR
Segura Campos
D000818:Animals; D001792:Blood Platelets / Q000187:drug effects; D002478:Cells, Cultured; D002784:Cholesterol / Q000737:chemistry; D003921:Diabetes Mellitus, Experimental; D004305:Dose-Response Relationship, Drug; D005260:Female; D005343:Fibrinolytic Agents / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D006949:Hyperlipidemias / Q000188:drug therapy; D008823:Micelles; D031299:Mucuna / Q000737:chemistry*; D010974:Platelet Aggregation / Q000187:drug effects; D011492:Protein Hydrolysates / Q000737:chemistry / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar
D005343:Fibrinolytic Agents; D008823:Micelles; D011492:Protein Hydrolysates; D002784:Cholesterol